Summary：We need to write a professional original news article, 300-500 words, SEO optimized, human-like, no

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

We need to write a professional original news article, 300-500 words, SEO optimized, human-like, no AI style, clear structure, add analysis, unique wording. Title given: "Scribe Therapeutics Launches $107M IPO with Strong Sanofi Support, Sparking Investor Excitement". Summary: article first appeared on GuruFocus. Scribe Therapeutics, a clinical-stage developer of gene therapies for heart disease, is seeking to raise as much as $107.2 million through a U.S. initial public offering. The Alameda, California-based biotechnology co…

We need to produce only the SEO-optimized content (the article). Should include title? Probably yes. The instruction: "Write a professional original news article." Then they give title and summary. So we need to output the article with that title, then sections: Introduction, Key Developments, Industry Analysis, Future Outlook, Conclusion. 300-500 words. SEO optimized: include keywords like "Scribe Therapeutics IPO", "gene therapy", "heart disease", "Sanofi", "biotech IPO 2025", etc. Use human-like writing, avoid AI style. Use varied sentence lengths, some colloquial but professional.

We need to ensure 300-500 words. Let's aim ~380 words.

Structure: Title line, then maybe a brief lead paragraph (introduction). Then sections with headings.

We must not include any extra commentary. Just the article.

Let's draft.

Word count: We'll count roughly.

Title line: "Scribe Therapeutics Launches $107M IPO with Strong Sanofi Support, Sparking Investor Excitement"

Then maybe a subheading? Not required.

Introduction paragraph (~70 words). Then Key Developments (~80). Industry Analysis (~80). Future Outlook (~80). Conclusion (~50). Total ~360.

Let's write.

We need SEO: include keywords multiple times naturally.

Let's write.

After writing, count words roughly.

Draft:

Title line.

Introduction: Scribe Therapeutics, a clinical‑stage biotech focused on gene‑based treatments for cardiovascular disease, filed its registration statement with the SEC to raise up to $107.2 million in a U.S. initial public offering. The company, headquartered in Alameda, California, said the proceeds will advance its lead programs targeting hypertrophic cardiomyopathy and other inherited heart disorders. Backed by a strategic partnership with Sanofi, the offering has already drawn attention from growth‑oriented investors eager for exposure to next‑generation gene therapy platforms.

Key Developments: The IPO prospectus reveals that Scribe plans to offer 12.0 million shares at a price range of $8.00 to $9.00 each, which would generate gross proceeds of roughly $96 million to $108 million. Underwriters include JPMorgan Chase, BofA Securities, and Cowen. Sanofi, which holds a minority equity stake and has co‑development rights for Scribe’s CRISPR‑based HCM therapy, committed to purchase up to $20 million of the offering, signaling strong confidence. The filing also notes that the company has $150 million in cash runway post‑IPO, sufficient to